知镜 Cognispect · 医学文献与研究工作台

Vedolizumab for De Novo Ulcerative Colitis After Kidney Transplantation in a Patient With IgA Nephropathy: A Case Report.

Cojocaru M, Dumbravă M, Sorohan BM.
Case reports in transplantation · 2026-07-14 · PMID 42454344

文献摘要

De novo inflammatory bowel disease (IBD) is a rare but important cause of diarrhea after kidney transplantation (KT). Experience with newer biological agents in the management of IBD among KT recipients remains limited. Vedolizumab is an α 4 β 7 integrin antagonist that selectively blocks a subset of gastrointestinal-homing lymphocytes, which limits systemic immunosuppression and, compared to other biologic agents or novel molecules, may reduce the risk of overimmunosuppression in the setting of KT. We report the case of a KT recipient with IgA nephropathy as the underlying cause of chronic kidney disease, who developed de novo ulcerative colitis after KT and was successfully treated with vedolizumab without experiencing adverse reactions during the 29 months of follow-up.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。